Novavax Inc Stock Price, News & Analysis

On April 4, 2023, Novavax, Inc. (Nasdaq: NVAX) announced its participation in the World Vaccine Congress (WVC) and the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The company will showcase data on its COVID-19 prototype vaccine as a booster and its COVID-Influenza Combination (CIC) vaccine. Key presentations include insights on vaccine hesitancy and safety surveillance, scheduled from April 3 to 6 in Washington, DC, and April 15 to 18 in Copenhagen, Denmark. Novavax is also a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards in two categories, with winners announced on April 4.

Novavax (Nasdaq: NVAX), a leader in protein-based vaccines, announced its participation in the TD Cowen's 43rd Annual Health Care Conference on March 8, 2023, from 9:50 – 10:20 a.m. EST. The conference will take place at the Boston Marriott Copley Place. John Trizzino, Chief Commercial Officer, will represent the company during a fireside chat moderated by Georgi Yordanov, an Equity Research Analyst in Biotechnology. A replay of the session will be accessible on Novavax's website for 90 days post-conference.

On March 2, 2023, Novavax announced the grant of stock options and restricted stock units to Elaine O'Hara, the newly appointed Chief Strategy Officer, effective March 1, 2023. The awards include a non-qualified stock option for 67,900 shares at an exercise price of $6.86, which vests over four years, and restricted stock units for 58,800 shares that vest over three years. These grants were made under the Novavax 2023 Inducement Plan and were approved to incentivize O'Hara's employment with the company. As a global leader in protein-based vaccines, Novavax continues to focus on developing key vaccines including those for COVID-19 and influenza.

Novavax, Inc. (Nasdaq: NVAX) reported fourth-quarter 2022 revenues of $357 million, a 61% increase year-over-year, and full-year revenues of $2.0 billion, reflecting 73% growth. The company updated its agreement with the U.S. government for an additional 1.5 million COVID-19 vaccine doses in 2023. Significant developments include the expansion of the Nuvaxovid™ label and initiation of a Phase 2 trial for a COVID-19-Influenza Combination vaccine. Despite a net loss of $182 million in Q4, down from $846 million in Q4 2021, cash reserves stand at $1.3 billion as of year-end 2022. Novavax aims to enhance efficiency and drive long-term value amid ongoing uncertainties.

Novavax, Inc. (NASDAQ: NVAX) will release its fourth quarter and full-year 2022 financial results on February 28, 2023, at 4:30 p.m. EST. The call will discuss operational highlights and include a Q&A session. Participants are encouraged to join early and can access the call through a webcast. A replay will be available from 7:30 p.m. EST on the same day until March 7, 2023. Novavax focuses on developing innovative vaccines for serious infectious diseases, enhancing vaccine efficacy through its patented Matrix-M adjuvant technology.

Novavax, Inc. (Nasdaq: NVAX) announced the extension of its agreement with the U.S. Department of Health and Human Services, securing up to 1.5 million doses of its COVID-19 vaccine, NVX-CoV2373. The modified agreement aims to enhance public access to the vaccine and includes plans for smaller dose vials and strain selection aligned with FDA guidance. The partnership highlights the importance of Novavax's protein-based vaccine in the U.S. COVID-19 vaccination campaign for 2023/2024. The vaccine is authorized for emergency use, primarily for individuals aged 12 and over, and will be provided free to states and healthcare partners.

On January 25, 2023, Novavax (NASDAQ: NVAX) announced the grant of inducement awards to its new President and CEO, John C. Jacobs, effective January 23, 2023. The awards include a non-qualified stock option for 290,700 shares at an exercise price of $11.92, with a ten-year term and a vesting schedule based on continued employment. Additionally, 249,590 restricted stock units will vest over three years. This action is in compliance with Nasdaq Listing Rule 5635(c)(4) and the 2023 Inducement Plan, reflecting the company's commitment to attracting top talent as it continues to develop next-generation vaccines.

Novavax, Inc. (NVAX) announced that its partner SK bioscience has received expanded approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid (NVX-CoV2373) to be used as a booster for COVID-19 in adults aged 18 and older. This decision follows prior recommendations from the Korean Centers for Disease Control and Prevention. The approval is based on data from Novavax's Phase 2 trials, which showed increased immune responses following the booster. Nuvaxovid is now authorized for use as a booster in over 35 countries. The vaccine utilizes Novavax's proprietary technology and is under review in additional markets for further indications.

Novavax, Inc. (Nasdaq: NVAX) announced that John C. Jacobs will succeed Stanley C. Erck as President and CEO effective January 23, 2023. Erck will assist in the leadership transition for 15 months. Jacobs brings over 25 years of industry experience, having led Harmony Biosciences through its IPO and FDA product approval. Under Erck's leadership since 2011, Novavax launched its COVID-19 vaccine in over 40 countries. The company is positioned to continue its strategic development with multiple vaccine candidates in progress.